Lipid Nanoparticles in Gene Therapy – Developing Trends and Competitive Landscape

Reasons to buy the ‘Lipid Nanoparticles in Gene Therapy’ report:

• Get a comprehensive overview of the evolution of gene therapy and LNPs.
• Obtain an in-depth insight into technology foresights, patent trends, and innovation and investment signals.
• Explore the challenges and road ahead in the LNPs in the gene therapy sector.
• Identify the key innovators associated with the LNP in gene therapy theme and gain a competitive edge in the market.

How is our ‘Lipid Nanoparticles in Gene Therapy’ report unique from other reports in the market?

• Understand the vectors for gene therapy delivery and evaluate non-viral vectors, particularly, lipid nanoparticles.
• Identify the key factors driving growth in the innovation and adoption of lipid nanoparticles for gene therapy delivery.
• Analyze companies developing LNP-based gene delivery innovations based on qualitative and quantitative information.

We recommend this valuable source of information to anyone involved in:

• ​​​​Pharmaceutical Industry (Big Pharma, Small Biotech, Start-Ups, etc.)
• Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
• Biotechnology companies
• Investment and Consulting Companies
• Gene therapy technology Companies and Start-ups

To Get a Snapshot of the Lipid Nanoparticles in Gene Therapy Report

Download a Free Report Sample

Lipid Nanoparticles in Gene Therapy Report Overview

Lipid nanoparticles (LNPs) have evolved from earlier generations of targeted drug delivery systems, demonstrating high efficiency in delivering antibodies, targeted drugs, and prodrugs. The mRNA-LNP combination is particularly well adopted for the immune system.

This “Lipid Nanoparticles in Gene Therapy” report discusses the developing trend and substantiates the assessment by analyzing signals and trends from various alternative datasets. The datasets include funding activity, clinical trials, and drug databases, all of which underscore the transformative potential of LNP-based gene delivery technology. The report further highlights the competitive landscape and identifies leading innovative companies and startups from an M&A perspective.

Buy The Full Report to Know More About the Lipid Nanoparticles in Gene Therapy

Download a Free Report Sample

Gene Therapy Value Chain

The key value chain components of gene therapy are gene therapy vectors, therapeutic oligonucleotides, genome editing, and oncolytic viruses. The key sub-components of gene therapy vectors are viral vectors and non-viral vectors.

Gene therapy is the introduction of exogenous, genetic material into cells to treat a disease. Gene therapies provide therapeutic benefits to patients, especially those suffering from monogenic diseases. Although cancers are generally not monogenic in origin, gene therapies are increasingly used to treat cancer by modifying gene regulation in tumorigenic pathways or by introducing genes that enhance the immune system’s ability to recognize and attack cancer cells.

Gene Therapy Value Chain

Buy The Full Report for More Insights into Lipid Nanoparticles in Gene Therapy

Download a Free Report Sample

Lipid Nanoparticles in Gene Therapy - Data Signals & Trends

The key pharma innovations are RNA-targeting small molecules, macrophage therapeutics, gene therapy for common diseases, gene delivery LNPs, and zinc-finger nucleases among others. According to the Innovation Radar framework of Technology Foresights, Gene therapy using LNPs is a high-impact innovation in the long term.

The US and China dominate innovation activity, receiving more than 60% of all patent applications related to LNPs for gene therapy. Notably, activity in the US surpassed China and other IP5 geographies (Europe, Japan, and South Korea) in the last three years (2021- 2023).

Buy The Full Report for More Insights into Lipid Nanoparticles in Gene Therapy

Download a Free Report Sample

Lipid Nanoparticles in Gene Therapy - Competitive Landscape

The leading innovators in gene delivery using LNPs are Sanofi, Moderna, BioNTech, Novartis, AstraZeneca, Pfizer, and Merck among others.

Sanofi: It is a pharmaceutical and healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, and multiple sclerosis; and human vaccines for protection against various bacterial and viral diseases. The company also offers consumer healthcare products for digestion; allergies;  cough,  cold,  flu, and sinus and supplements. Sanofi’s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines.

Leading Innovators In Gene Delivery Using Lnps

Buy The Full Report for More Insights into Innovative Companies’ Gene Therapy using LNP

Download a Free Report Sample

Lipid Nanoparticles in Gene Therapy - Leading Universities

Some of the leading universities & research institutions in LNP-assisted gene delivery are the University of Pennsylvania, Massachusetts Institute of Technology, University of Carolina, and Harvard University among others. Massachusetts  Institute of Technology entered into a research collaboration agreement with healthcare company Novo Nordisk, to develop mechanisms for oral drug delivery. One of the breakthroughs included a lipid nanoparticle formulation to carry out mRNA to the lungs.

Leading Universities & Research Institutions In LNP-Assisted Gene Delivery

Buy The Full Report for More Insights into Leading Universities in the Lipid Nanoparticles in Gene Therapy

Download a Free Report Sample

Key Highlights

• Gene therapy is increasingly gaining attention and lipid nanoparticles are most preferred non-viral vectors for delivering gene therapy
• Innovation in lipid nanoparticles for gene therapy is growing steadily and the growth is compounded by investments and M&A activities
• Competitive landscape in lipid nanoparticles innovation has 50+ key innovation leaders and 40+ startups and small biotech addressing challenges in LNP-based gene delivery.